EPIDEP: Prevalence of undiagnosed depression in an epilepsy outpatient clinic
EPIDEP: Распространённость недиагностированной депрессии в амбулаторной эпилептологической клинике
2025-08-09
SCID: 54.1/mxtwuptt
Discuss with AI
NDDIE screening toolSSRI treatmentdrug-resistant epilepsyepilepsy outpatientsundiagnosed depression
Figures from the paper
Abstract (AI)
Epilepsy and depression frequently coexist, with depressive symptoms affecting up to 50 % of patients, particularly those with drug-resistant epilepsy (DRE). Underdetection of depression in general neurology settings can worsen seizure control, treatment adherence, and overall prognosis. This study aimed to characterize the prevalence of undiagnosed depression in epilepsy outpatients and to evaluate the Neurological Disorders Depression Inventory for Epilepsy (NDDIE) as a screening tool, as well as the impact of early SSRI treatment. In a single-center, observational, non-interventional, prospective design, 82 consenting adults (mean age 50.8 ± 23 years; 59.8 % female) with diagnosed epilepsy (focal, idiopathic generalized, or unknown onset) and no prior psychiatric history or antidepressant use were enrolled over one year. Participants completed the NDDIE at baseline; those screening positive (score > 13) began SSRI therapy and were referred to psychiatry for diagnostic confirmation. Repeat NDDIE assessments occurred at three months. Of 82 patients, 35 (42.7 %) screened positive on NDDIE and 24 (29.3 % overall) were confirmed depressed by psychiatry (κ = 0.71). Baseline mean NDDIE was 12.17 ± 5.46, decreasing to 10.78 ± 4.36 at three months across all participants (Δ = 1.39; p < 0.05). In treated patients (n = 35), NDDIE fell from 17.83 ± 2.74 to 14.74 ± 3.48 (Δ = 3.09; p < 0.001). Patients with DRE (n = 10) had higher baseline scores than non-DRE (19.40 ± 1.96 vs 11.00 ± 5.40; p < 0.05) and those on ≥ 2 anti-seizure medications (ASM) scored higher than monotherapy (17.52 ± 4.08 vs 9.82 ± 4.20; p < 0.001). Patients > 60 years had lower scores than younger patients (10.68 ± 4.58 vs 13.23 ± 5.82; p < 0.05). No sex or epilepsy type differences were significant. Depression is common and underdiagnosed in epilepsy outpatients, especially among those with DRE or on multiple ASMs. The NDDIE demonstrates good agreement with psychiatric diagnosis and detects clinically meaningful improvements following early SSRI treatment. Systematic depression screening using NDDIE in neurology clinics is recommended to identify and treat comorbid depression, potentially improving quality of life and seizure outcomes.
Key Findings
1
Depression was common and underdiagnosed: 35 of 82 patients (42.7%) screened positive, while 24 (29.3%) received psychiatric confirmation.
2
NDDIE scores decreased significantly after three months, particularly among SSRI-treated patients, declining from 17.83 ± 2.74 to 14.74 ± 3.48 (p < 0.001).
3
Patients taking at least two antiseizure medications had higher depression scores than those receiving monotherapy, whereas older patients had lower scores; sex and epilepsy type showed no significant differences.
4
Patients with drug-resistant epilepsy had higher baseline depression scores than non-drug-resistant patients (19.40 ± 1.96 vs 11.00 ± 5.40; p < 0.05).
5
The NDDIE showed good agreement with psychiatric diagnosis, with Cohen’s κ = 0.71, supporting its use for depression screening in epilepsy outpatients.
Research Object
adults with diagnosed epilepsy attending an outpatient clinic
Research Subject
the prevalence and underdiagnosis of depression, along with NDDIE screening performance and changes following early SSRI treatment
Publication Details
Publication Date
2025-08-09
Journal
Publisher
ISSN
Cited by
3
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest